5 results about "B Antibody" patented technology

The present invention provides a specific antibody against FGFR2IIIb. Specifically, the invention provides an anti-FGFR2IIIb antibody or an antigen binding fragment thereof, and the anti-FGFR2IIIb antibody or the antigen binding fragment thereof can effectively bind human, mouse and monkey FGFR2IIIb. The invention also provides an antibody drug conjugate and the like of the antibody or the antigen binding fragment, can be applied to preparation of drugs for treating tumors expressing or overexpressing FGFR2IIIb, and has a good application prospect.

Provided herein are antibodies that specifically bind to MICA / B having heavy chain, light chain, variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) disclosed herein, as well as methods and uses thereof.

This invention discloses a composite material based on hollow mesoporous carbon spheres loaded with ABO blood group monoclonal antibodies, comprising hollow mesoporous carbon spheres and ABO blood group monoclonal antibodies loaded on the hollow mesoporous carbon spheres, wherein the ABO blood group monoclonal antibodies are selected from at least one of type A antibodies and type B antibodies. This invention also discloses a method for preparing the composite material, comprising: modifying the surface of the hollow mesoporous carbon spheres with amino groups; dispersing the spheres in an ABO blood group monoclonal antibody solution; and stirring the reaction. This invention immobilizes ABO blood group monoclonal antibodies on the surface of hollow mesoporous carbon spheres, improving the stability, specificity, and sensitivity of the antibodies, and achieving rapid and accurate ABO blood group identification. This invention also discloses a kit comprising the above-mentioned composite material, and the application of this composite material in ABO blood group detection.

This specification provides a method for treating cancer using an antibody or antigen-binding fragment thereof that specifically binds to MICA / B, having a heavy chain, a light chain, a heavy chain variable domain (VH), a light chain variable domain (VL), and a complementarity-determining region (CDR) as disclosed herein. In a second aspect, this disclosure provides a method for treating parotid gland cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody that binds to MICA / B (an anti-MICA / B antibody).